Suchergebnisse - "Storniolo, Anna"

PubPharm (17)

1

BRE12-158 : A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Schneider, B. | Jiang, G. | Ballinger, T. | +30

CommentIn: J Clin Oncol. 2022 Jun 10;40(17):1962-1963. - PMID 35357888

2

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer : Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Adams, S. | Othus, M. | Patel, S. | +25

3

Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Sardesai, S. | Thomas, A. | Gallagher, C. | +14

4

Updated Results of TBCRC026 : Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Connolly, R. | Leal, J. | Solnes, L. | +20

CommentIn: Radiol Imaging Cancer. 2021 Sep;3(5):e219021. - PMID 34533375

5

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer : Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial

enthalten in: JAMA oncology | 2020

von Radovich, M. | Jiang, G. | Hancock, B. | +30

CommentIn: JAMA Oncol. 2020 Sep 1;6(9):1332-1333. - PMID 32644099

6

TBCRC 032 IB/II Multicenter Study : Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Lehmann, B. | Abramson, V. | Sanders, M. | +16

7

TBCRC 002 : a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

enthalten in: Breast cancer research : BCR | 2020

von Vaklavas, C. | Roberts, B. | Varley, K. | +15

8

TBCRC023 : A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Rimawi, M. | Niravath, P. | Wang, T. | +17

9

TBCRC026 : Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Connolly, R. | Leal, J. | Solnes, L. | +20

CommentIn: J Clin Oncol. 2019 Aug 10;37(23):2091-2092. - PMID 31251692

10

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms : the ZAP trial

enthalten in: Breast cancer research and treatment | 2018

von Santa-Maria, C. | Bardia, A. | Blackford, A. | +15